Entries by Iptor

Business Consultant – Publishing (United States)

General: As a Business Consultant, you contribute to the profitability of the Professional Services (PS) business line, specifically providing and delivering first-class services and support across Iptor’s product portfolio, by understanding customer business requirements to ensure added-value solution. Responsibilities of this role include, but are not necessarily limited to, the duties listed on this job […]

Three IT considerations for long-term sustainability around DSCSA compliance

The Drug Supply Chain Security Act (DSCSA) isn’t exactly news to the pharmaceutical industry. But it still presents many challenges for distributors to overcome. The law was passed in 2013, and entities all along the drug supply chain have had years to adapt to its new requirements for unit-level traceability of prescription drugs. The law […]

Why haven’t pharmaceutical distributors embraced the cloud?

It seems almost counterintuitive to write a blog post, at this moment in 2021, advocating for the use of cloud solutions as the foundation of a business’ computing infrastructure. It’s been 14 years since Google CEO Eric Schmidt introduced the phrase into the common vernacular, and the idea behind cloud computing has been around much […]

Business Consultant (United States / Remote)

General: As a Business Consultant, you will contribute to the profitability of the Professional Services (PS) business line, specifically by providing and delivering first-class services and support across Iptor’s product portfolio, and by understanding customer business requirements to ensure an added-value solution. Responsibilities may include, but are not necessarily limited to, the duties listed on […]

3 Reasons Pharma Distributors Should be Wary of Pandemic-Related DSCSA Exemptions

The Drug Supply Chain Security Act (DSCSA) obligates US pharmaceutical manufacturers, wholesale distributors, dispensers and re-packagers to participate in an interoperable exchange that monitors the distribution of drugs to prevent counterfeit or contaminated drugs. However, for pharmaceutical distributors, the COVID-19 pandemic constitutes a public health emergency that automatically excludes certain activities from DSCSA requirements. COVID-19 […]